Galecto, Inc.

NasdaqCM GLTO

Galecto, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -1,675.62%

Galecto, Inc. Operating Income Margin is -1,675.62% for the Trailing 12 Months (TTM) ending September 30, 2024. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqCM: GLTO

Galecto, Inc.

CEO	Dr. Hans T. Schambye M.D., Ph.D.
IPO Date	Oct. 29, 2020
Location	United States
Headquarters	75 State Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Key trends

Past 5 years